A new study looked at the effectiveness of the modified National Institute of Health (mNIH) activity and chronicity scoring system for predicting end-stage kidney disease (ESKD) among Latin American individuals with lupus nephritis (LN).
This retrospective study included 412 Colombian participants with biopsy-confirmed LN. The median age at the time of biopsy was 29 years. The study cohort was predominantly females, accounting for 87.6% of the participants. Of the 412 participants, 84 (20.4%) progressed to ESKD after a median time of three months following the biopsy. Additional analysis showed that participants who did not respond to induction therapy treatment at 6 months had a significantly increased the risk of ESKD. Furthermore, non-response to immunosuppressive therapies were more common in individuals who developed ESKD (52.9%) compared to those who did not (24.9%). These findings were consistent with prior research. Overall, mNIH activity and chronicity indices identified a correlation with a heightened risk of ESKD. Additionally, the presence of fibrous crescents and fibrinoid necrosis were found to be significant predictors, leading to faster progression to ESKD and ultimately a shortened kidney lifespan.
This study highlights the predictive value of kidney biopsy in LN and the need for improved predictors for poor long-term kidney outcomes, given that current therapies for LN are not sufficiently effective at inducing remission. While the mNIH’s scoring system has utility as a valuable prognostic tool for assessing ESKD risk, larger scale studies with more diverse patient populations are needed.
Learn more about kidney health and lupus.
This post was originally published on this site